Kiniksa Pharmaceuticals, Ltd. Ratios | P/E, ROE & Valuation

On this page, KNSA's current P/E is 74.7, compared with a multi-year average around 55.9. A higher P/E versus its own history is a calculated premium versus that average—not a conclusion that the stock is expensive. Cross-check profitability (ROE/ROIC), liquidity (current ratio), and leverage (debt-to-equity) so the multiple is read with those published figures.

Market cap is the market value of a company's equity and is commonly calculated as share price multiplied by shares outstanding. The latest market cap shown in the table is $6.09B. Pair market cap with valuation multiples (P/E, P/B, P/S) so you can evaluate whether size also corresponds with "quality" and profitability. For a wider view across stocks, you can also use the stock screener.

There is no P/E Tickerplace rates as good. Compare the P/E on this page with Kiniksa Pharmaceuticals, Ltd.'s own historical range (in the table) and with peers via the Screener and Compare tools. A higher or lower multiple versus peers is a calculated gap, not a recommendation.

The fastest way to compare Kiniksa Pharmaceuticals, Ltd. with competitors is to use the built-in "Peers Comparison" section on this page and the Compare tool. Focus on a small set of ratios that work together: P/E for valuation, ROE/ROIC for profitability and capital efficiency, current ratio and interest coverage for liquidity and solvency, and debt-to-equity for leverage risk. When you see Kiniksa Pharmaceuticals, Ltd. outperform peers on profitability while keeping valuation and leverage reasonable, it often signals stronger fundamentals.

Liquidity and leverage figures on this page are published ratios, not a verdict that Kiniksa Pharmaceuticals, Ltd. is financially strong. Current ratio is about 3.90, which is above 1.0 and can indicate more comfortable short-term liquidity. Interest coverage is about 0.00, implying less buffer for servicing interest costs. Debt-to-equity is about 0.01, suggesting leverage is more moderate relative to a high-debt profile. Pair them with ROE/ROIC and cash-flow rows in the table. Tickerplace does not rate the company as a good or poor investment.

Ratios are a way to see what the business is likely to sustain. Look for upward trends in profitability metrics (ROE and ROIC), improving earnings/cash-flow backed measures, and stable or strengthening liquidity. If Kiniksa Pharmaceuticals, Ltd. is sustaining strong returns (for example ROE at 13.65% and ROIC at 9.71%) while debt levels and interest coverage remain manageable, growth expectations may be more credible. If valuation multiples expand while returns weaken, the market may be pricing optimistic growth ahead of results.